Psychoplastogens: A Novel Therapeutic Approach for Neurological Diseases and Disorders.
ACS Medicinal Chemistry Letters September 14, 2023 DOI: 10.1021/acsmedchemlett.3c00309 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | ketamine scopolamine N N-dimethyltryptamine rapastinel |
| Topics | Neuroplasticity |
| Keywords | Mental health Psychopharmacology Therapeutic research |
| Citations | 3 |
| Key findings | Psychoplastogens show potential for treating neurological disorders by modulating synaptic connections and plasticity. |
Abstract
Neurological diseases often involve changes in synaptic connectivity and plasticity. Psychoplastogens, substances that stimulate neuronal growth and enhance neural structures, show promise in mitigating these changes. They activate key biological targets, including AMPA receptors, TrkB, and mTOR. Substances like ketamine, scopolamine, N,N-dimethyltryptamine, and rapastinel have psychoplastogenic properties. In clinical trials, psychedelic psychoplastogens have demonstrated antidepressant, anxiolytic, and anti-addictive effects. The research described in this Patent Highlight suggests the potential for novel therapies in neurological disorders that leverage psychoplastogens, which modulate synaptic connections and plasticity.